Within that pipeline, Biogen has five experimental drugs in late-stage testing that it classifies as programs with “significant commercial potential.” The list includes two potential lupus therapies, named litifilimab and dapirolizumab pegol, as well as an immune system-regulating antibody that the company got ahold of through a $1.2 billion acquisition . That antibody, “felzartamab,” is being evaluated against several kidney illnesses.The executive team “has been out meeting with investors and analysts on ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Sanofi ( SNY ) announced the acquisition of Dynavax ( DVAX ) for $15.50 per share, or $2. ...